ACXP

Acurx Pharmaceuticals, Inc. (ACXP) - Q2 2025 10-Q Summary

Business Context and Reporting Period

Acurx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing a novel class of antibiotics targeting Gram-positive bacterial infections. The lead product candidate, ibezapolstat, is in development for the treatment of Clostridioides difficile infections (CDI). This report covers the quarterly period ended June 30, 2025. The company is classified as an emerging growth company and a smaller reporting company.

Key Financial Metrics

Material Changes vs. Prior Period

• Expense Reduction: Total operating expenses decreased by approximately 48% year-over-year (from $8.5M to $4.4M). This was driven by a 67% decrease in R&D expenses (due to lower manufacturing and consulting fees) and a 35% decrease in G&A expenses (primarily due to reduced share-based compensation and professional fees).
• Financing Activity: The company raised approximately $6.1 million in net proceeds from financing activities during the six months ended June 30, 2025. This included proceeds from a January Registered Direct Offering ($2.1M), a March Registered Direct Offering ($0.9M), an Equity Line of Credit (ELOC) ($0.6M), and a warrant inducement exercise ($2.5M).
• Share Count: The number of common shares outstanding increased from 851,534 at December 31, 2024, to 1,470,352 at June 30, 2025, due to equity issuances and warrant exercises.
• Reverse Stock Split: On August 4, 2025, the company effected a 1-for-20 reverse stock split. All per-share data in this filing has been adjusted retroactively to reflect this split.

Guidance, Outlook, and Risks

• Liquidity and Going Concern: Management states that as of June 30, 2025, the company's cash balance of approximately $6.1 million is not sufficient to meet anticipated cash requirements for at least 12 months. The company's independent auditor has expressed substantial doubt about its ability to continue as a going concern. Additional equity financing or grant funding is required to sustain operations.
• Nasdaq Compliance: The company received notices from Nasdaq regarding non-compliance with the Minimum Stockholders' Equity Requirement (received March 25, 2025) and the Minimum Bid Price Requirement (received February 24, 2025). A compliance plan was submitted for the equity requirement. The company has until August 25, 2025, to regain compliance with the bid price requirement or risk delisting.
• Capital Resources: The company has an active ELOC with Lincoln Park Capital Fund, LLC, committed to purchase up to $12.0 million of common stock. As of August 8, 2025, approximately $1.6 million had been sold under this agreement.
• Development Outlook: The company continues to advance ibezapolstat. It expects to partner with a fully-integrated pharmaceutical company for late-stage clinical trials and commercialization or conduct Phase 3 trials prior to such a partnership.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $6.1M cash balance against current burn rates and the timeline for the next financing round.
• Nasdaq Status: Monitor the status of the compliance plans for the Minimum Stockholders' Equity and Minimum Bid Price requirements to assess delisting risk.
• Dilution Impact: Review the terms of the ELOC and recent warrant exercises to understand the potential for further shareholder dilution.
• Going Concern Opinion: Confirm the auditor's stance on the company's ability to continue operations in the upcoming fiscal year.
• Reverse Stock Split: Ensure all financial data is viewed on a post-split basis (1-for-20) as reflected in the filing.